Treatment of HIV and risk of multiple sclerosis

Epidemiology

Volumn 24, Issue 2, 2013, Pages 331-332

  Nexø, Bjørn Andersen ^a   Pedersen, Lars ^b   Sørensen, Henrik Toft ^b   Koch Henriksen, Nils ^b,c,d  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

DISEASE ASSOCIATION; DISEASE COURSE; DISEASE REGISTRY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MORTALITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RISK FACTOR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DENMARK; HIV INFECTIONS; HUMANS; INCIDENCE; MULTIPLE SCLEROSIS; RISK;

EID: 84873328764     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0b013e318281e48a     Document Type: Letter

References (6)

1. Perron H, Garson JA, Bedin F, et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci U S A. 1997;94:7583-7588.
2. Nexøb A, Christensen T, Frederiksen J, et Al. the Etiology of Multiple Sclerosis: Genetic Evidence for the Involvement of the Hum. Endogenous Retrovirus HERV-Fc1. PLoS ONE. 2011;6:e16652.
3. Maruszak H, Brew BJ, Giovannoni G, Gold J. Could antiretroviral drugs be effective in multiple sclerosis? A case report. Eur J Neurol. 2011;18:e110-e111.
4. Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287:2398-2399.
5. Brønnum-Hansen H, Koch-Henriksen N, Stenager E. The Danish Multiple Sclerosis Registry. Scand J Public Health. 2011;39(7 suppl):62-64.
6. Poole C. Beyond the confidence interval. Am J Public Health. 1987;77:195-199.